gvtcx

Insulin Pumps, Continuous Glucose Monitoring, Products Contributing to the Delivery of Hybrid Closed Loop Pathways and Associated Products

Supply Chain Coordination Limited Published 6 Feb 2025 Contracts Finder

key details

Value£1,067,000,000
Statuscomplete
Category (CPV) 33140000 +4 more
Deadline10 Mar 2025
Contract start28 Nov 2025
Contract end27 Nov 2027
Procedureopen
SME suitableYes
OCIDocds-b5fd17-13650ef2-0040-42d4-98e9-af1283571b69

Awards (12)

This procurement was awarded to 12 suppliers. Values shown are per-award; the notice total is £1,067,000,000.

SupplierValueDateStatus
Abbott Laboratories Limited shared £1,067,000,000 5 Nov 2025 active
Advanced Therapeutics (UK) Ltd shared £1,067,000,000 5 Nov 2025 active
Air Liquide Healthcare Ltd shared £1,067,000,000 5 Nov 2025 active
Dexcom International Ltd shared £1,067,000,000 5 Nov 2025 active
Glooko Limited shared £1,067,000,000 5 Nov 2025 active
GlucoRx Ltd shared £1,067,000,000 5 Nov 2025 active
Insulet International Ltd shared £1,067,000,000 5 Nov 2025 active
Medtronic Limited shared £1,067,000,000 5 Nov 2025 active
Medtrum Ltd shared £1,067,000,000 5 Nov 2025 active
Novo Nordisk shared £1,067,000,000 5 Nov 2025 active
Urathon Europe Limited shared £1,067,000,000 5 Nov 2025 active
Ypsomed Ltd shared £1,067,000,000 5 Nov 2025 active

description

NHS Supply Chain seeks to establish a Framework Agreement for the supply of Insulin Pumps, Continuous Glucose Monitoring, Products Contributing to the Delivery of Hybrid Closed Loop Pathways and Associated Products. This includes but not limited to tethered and patch insulin pumps, continuous glucose monitoring devices, products that contribute to the functionality of hybrid closed loop insulin delivery systems, and consumables. Precise quantities are unknown. It is anticipated in the first year that spend will be approximately £ 240,000,000 - £267,000,000 GBP (Excluding VAT), however this is approximate only and may vary depending on requirements of bodies purchasing under the Framework. Estimated total value over the 4 year agreement is approximately £960,000,000 to £1,067,000,000 Excluding VAT. Please note it is expected that the yearly spend for years 2 , 3 and 4 of the Framework Agreement will rise significantly. Following the National Institute for Health and Care Excellence (NICE) Technology Appraisal TA943 Overview | Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes | Guidance | NICE published 19th December 2023 and the NHS England Implementation Plan https://www.england.nhs.uk/long-read/hybrid-closed-loop-technologies-5-yearimplementationstrategy/

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

5 notices published against this procurement.

PublishedTypeRegimeNotice
7 Nov 2024 Planning (planning) · 1fd3ec74-42c5-4671-be54-2a9da934c18f-800628
4 Mar 2025 Tender amendment (tenderAmendment) · 74d15369-6ea1-4168-a1df-d95c3f83d450-831725
3 Dec 2025 Award (award) · e2997ca2-77d7-4e3e-80ae-017b0d61b828-874606
6 Feb 2026 Preliminary market engagement (UK2) Procurement Act 2023 010763-2026
10 Feb 2026 Preliminary market engagement (UK2) Procurement Act 2023 011652-2026

more from Supply Chain Coordination Limited

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.